- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Extended release opioid may help ease chronic neuropathic pain
An abstract presented at the American Academy of Pain Medicine meeting in San Antonio suggests that an extended-release oxymorphone (brand name: Opana) formula could be a reasonable treatment option for cancer patients needing long-term neuropathic pain management.
Chronic pain is divided into two types:
Nocioceptive: the pain moves along normal nerve pathways (described as dull or throbbing)
Neuropathic: the pain is caused by damage to the central nervous system (described as burning, shooting, radiating).
Traditionally, opioids are first-line therapy to treat nocioceptive pain, but are often third-line therapy for neuropathic pain. This small study, sponsored by Endo Pharmaceuticals (makers of Opana) suggests that extended-release oxymorphone may offer some benefit for patients suffering from chronic neuropathic pain.
Source: Slatkin N, et al. Long-term management of neuropathic cancer pain with oxymorphone extended release: Results of a 1-year open-label extension trial AAPM 2010; Abstract 117.